The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
Open accessAbstract
Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and methods: Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA). Results: A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059). Conclusions: The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Self-citationvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Self-citationSikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Self-citationLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Self-citationDissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Self-citationThe Role of BRCA1 in the Cellular Response to Chemotherapy
Kennedy, R. D., Quinn, J. E., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh312 · Cited by 430
Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 419
Self-citationHahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A., Denkert, C., Fasching, P. A., Blohmer, J. U., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
Self-citation
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationBurstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz235 · Cited by 667
Self-citationThe Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 283
Metadata
- Authors
- Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kümmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A.-R., von Minckwitz, G., & Untch, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 29
- Issue
- 12
- Pages
- 2341-2347
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2895846919
- Cited by
- 295
- References
- 20
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. https://app.cochat.ai/papers/10.1093/annonc/mdy460
- The paper
- Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kümmel, S., Schem, C., . . . Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. Annals of Oncology. https://doi.org/10.1093/annonc/mdy460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.